Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia

Post-stem cell transplantation (SCT) relapsed acute lymphoblastic leukemia (ALL) has extremely poor prognosis with median survival of less than 1 year. Donor lymphocyte infusion, second transplantation, chemotherapy or cytokine treatment have been tried as a salvage regimen without significant clini...

Full description

Saved in:
Bibliographic Details
Published in:Immunotherapy 2016-07, Vol.8 (8), p.847-852
Main Authors: Alcharakh, Mohammed, Yun, Seongseok, Dong, Yimin, Vincelette, Nicole D, Daud, Madiha, Manzoor, Saima, Riaz, Irbaz Bin, Anwer, Faiz
Format: Article
Language:English
Subjects:
Acute lymphoblastic leukemia
Antigens
biphenotypic acute leukemia
Blinatumomab
Bone marrow
Cancer therapies
Case reports
CD19
CD19 antigen
CD3 antigen
Cell activation
Cell lineage
Chemotherapy
Cytokines
Flow cytometry
Leukemia
Lymphatic leukemia
Lymphocytes
Lymphocytes B
Lymphocytes T
Medical prognosis
Monoclonal antibodies
Patients
Philadelphia chromosome
Population
Remission
Stem cell transplantation
Stem cells
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Post-stem cell transplantation (SCT) relapsed acute lymphoblastic leukemia (ALL) has extremely poor prognosis with median survival of less than 1 year. Donor lymphocyte infusion, second transplantation, chemotherapy or cytokine treatment have been tried as a salvage regimen without significant clinical benefit. Recently, blinatumomab, a bispecific monoclonal antibody targeting CD3-expressing T cells and CD19-expressing B-cell lineage malignant cells demonstrated promising outcomes in relapsed/refractory ALL patients. Literature on blinatumomab use in biphenotypic ALL along with Philadelphia chromosome positive (Ph ) ALL is limited. We report a case of post-SCT relapsed CD19 expressing biphenotypic lymphoblastic leukemia patient who achieved complete remission after blinatumomab treatment and has lasting remission for 1 year.
ISSN:1750-743X
1750-7448
DOI:10.2217/imt-2015-0023